Clinical trial NCT04480788: CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
Official title: Early Clinical Study on Increasing Dose and Open Label of T Cell Injection Targeting CD7 Autologous Chimeric Antigen Receptor in the Treatment of Relapsed / Refractory CD7 Positive Hemolymph System Malignancies
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: T Lymphoblastic Leukemia/Lymphoma
Extramedullary NK-T-cell Lymphoma, Nasal Type
Peripheral T-cell Lymphoma, Nonspecific
Angioimmunoblastic T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Anaplastic Large Cell Lymphoma, ALK-negative
T-cell Lymphoblastic Leukemia
Lead sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: The First Affiliated Hospital of Zhengzhou University
First posted: 2020-07-21
Enrollment: 9
Sex: ALL
Minimum age (years): 7
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: CD7-CART
Primary purpose: TREATMENT

Brief summary: Phase I was a single arm, open label, dose increasing study to explore the safety, tolerance and Cytodynamic characteristics of the drug, and to preliminarily observe the efficacy of the study drug in relapsed / refractory CD7 Positive hematolymph system malignant tumor patients, so as to explore the clinical applicable dose of phase II. Since the activity and toxicity of cellular drugs (long-term survival drugs) do not have obvious dose dependence, and the increase of their dose may be accompanied by the increase of toxicity, rather than necessary for therapeutic effect, it is not necessarily suitable to recommend the effective dose according to the maximum tolerable dose (MTD). Therefore, this study will be based on the safety data, as well as the preliminary efficacy, efficacy and drug The end point of pharmacokinetics (ORR, the content of CD7 Positive Cells, the expansion and duration of car-t cells) were comprehensively considered to determine the recommended dose for phase II clinical trial.Main research purposes Objective to evaluate the safety and tolerability of T cell injection targeting CD7 autologous chimeric antigen receptor in the treatment of relapsed / refractory CD7 Positive hematological and lymphoid malignancies.


Eligibility criteria: Inclusion Criteria:

* The age ranged from 7 to 70 years (including the cut-off value), regardless of gender
* The expected survival time was more than 6 weeks
* ECOG score 0-1
* Malignant lymphoma (including but not limited to acute T-lymphoblastic leukemia / lymphoma; extramedullary NK / T-cell lymphoma, nasal type; peripheral T-cell lymphoma, nonspecific; vascular immunoblastic T-cell lymphoma; intestinal disease associated T-cell lymphomas; anaplastic large cell lymphoma (ALK -); T-cell lymphoblastic leukemia)
* When screening, hematological malignancies with CD7 Positive confirmed by bone marrow examination or tumor pathology with positive rate of CD7 ≥ 30%, meeting one of the following conditions:

  1. At least two chemotherapy regimens failed or did not achieve complete remission or relapse;
  2. Patients who relapsed after stem cell transplantation were not affected by other treatment methods;
* For peripheral blood involved acute T-lymphoblastic leukemia / lymphoma and NK / T-cell lymphoma, patients with TCR rearrangement were detected by ngs
* The liver and kidney function, heart and lung function meet the following requirements:

  1. Creatinine ≤ 1.5 ULN;
  2. LVEF ≥ 45%;
  3. Blood oxygen saturation \> 91%;
  4. The total bilirubin ≤ 2 × ULN; ALT and AST ≤ 2.5 × ULN; the abnormal ALT and AST caused by diseases (such as liver infiltration or bile duct obstruction) can be relaxed to ≤ 5 × ULN;
* Understand the experiment and have signed the informed consent

Exclusion Criteria:

* Those who need immunosuppressant;
* For intestinal disease-related T-cell lymphoma, patients with intestinal ulcer or hematochezia were examined by colonoscopy;
* In addition to cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical operation, and breast ductal carcinoma in situ after radical operation;
* The patients with positive HBsAg or HBcAb and HBV DNA titer in peripheral blood were not within the normal reference value; those with positive anti HCV antibody and positive HCV RNA in peripheral blood; those with HIV antibody positive and cytomegalovirus DNA positive Syphilis was positive;
* Severe heart disease: including but not limited to unstable angina pectoris, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥ III), severe arrhythmia;
* Unstable systemic diseases judged by researchers: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
* Within 7 days before screening, there were active or uncontrollable infections requiring systemic treatment (except for mild genitourinary system infection and upper respiratory tract infection);
* Pregnant or lactating women, female subjects planning pregnancy within 1 year after cell reinfusion or male subjects whose partners plan to conceive within 1 year after cell reinfusion;
* Patients who had received car-t therapy or other gene modified cell therapy before screening;
* Subjects who were receiving systemic steroid therapy or were receiving systemic steroid therapy for 7 days were excluded;
* Participated in other clinical studies within 3 months before screening;
* There was evidence of central nervous system invasion during screening;
* According to the judgment of the researchers, it does not conform to the condition of cell preparation;
* Other researchers think it is not suitable to be included in the study.

Primary outcomes:
measure: Dose-limiting toxicity (DLT)
timeFrame: Up to 2 years
Secondary outcomes:
measure: Safety results
timeFrame: Up to 2 years
measure: PK
timeFrame: Up to 2 years
measure: PK
timeFrame: Up to 2 years
measure: PK
timeFrame: Up to 2 years
measure: PD
timeFrame: Up to 2 years
measure: PD
timeFrame: Up to 2 years
measure: ORR
timeFrame: Up to 2 years
measure: overall survival (OS)
timeFrame: Up to 2 years
measure: Search Results Featured snippet from the web Duration of response (DOR)
timeFrame: Up to 2 years
measure: Progression-free survival (PFS)
timeFrame: Up to 2 years
measure: Immunogenicity
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: First Affiliated Hospital of Zhengzhou University
state: Henan
Study officials:
References: